Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32669978 | 0.86 | COMT (0.35) | COMTFTOKMT2AFFAR1 | |
| SCHEMBL32669636 | 0.85 | COMT (0.37) | COMTFTOKMT2AFFAR1 | |
| SCHEMBL32670134 | 0.85 | COMT (0.34) | COMTFTOKMT2AFFAR1 | |
| SCHEMBL32669527 | 0.84 | CYP2A6 (0.42) | COMTFTOFFAR1 | |
| SCHEMBL32669511 | 0.83 | COMT (0.39) | COMTFTO | |
| SCHEMBL32670018 | 0.81 | COMT (0.35) | COMTFTO | |
| SCHEMBL32669982 | 0.80 | COMT (0.35) | COMTFTO | |
| SCHEMBL32669704 | 0.79 | FTO (0.60) | COMTFTOKMT2A | |
| SCHEMBL32669904 | 0.79 | SLC22A12 (0.33) | COMTFTO | |
| SCHEMBL32669922 | 0.77 | MEN1 (0.38) | COMTFTOKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | NSD2 888/4885COMT 52/4885FTO 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.